linjc16/ctgov huggingface dataset:
Biomarker for Rapid Diagnosis of Hemispheric Stroke

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments [NR2-peptide] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.

Official Title
-----------------
Biomarker for Rapid Diagnosis of Hemispheric Stroke

Conditions
-----------------
Acute Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hemiparesis at least one sign of cortical involvement (e.g., aphasia, neglect, gaze deviation, reduced level of consciousness) hospital admission within 4.5 hours after symptom onset Exclusion Criteria: stroke/TIA within the last 3 months traumatic brain injury within the last 3 months history of brain tumor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage) |  | 9 months |
Pantoprazole in Cisplatin Nephrotoxicity

Study Overview
=================
Brief Summary
-----------------
Pantoprazole in Cisplatin Nephrotoxicity

Detailed Description
-----------------
Pantoprazole in Cisplatin NephrotoxicityPantoprazole in Cisplatin Nephrotoxicity. Is it protective?

Official Title
-----------------
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer

Conditions
-----------------
Oncology

Intervention / Treatment
-----------------
* Drug: Pantoprazole low dose
* Drug: Pantoprazole high dose
* Other: Standard hydration
* Drug: Cisplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with head and neck cancer Exclusion Criteria: GFR less than 59. DM Elevated liver enzymes more than 3 fold.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard hydration alone<br>Cisplatin with standard hydration | Other: Standard hydration<br>* Standard hydration alone<br>* Other names: Hydration;Drug: Cisplatin<br>* Cisplatin<br>|
| Active Comparator: Pantoprazole high dose<br>Cisplatin with standard hydration with pantoprazole 1.6 mg/kg | Drug: Pantoprazole high dose<br>* Pantoprazole 1.6 mg\kg<br>* Other names: zurcal, Controloc;Other: Standard hydration<br>* Standard hydration alone<br>* Other names: Hydration;Drug: Cisplatin<br>* Cisplatin<br>|
| Active Comparator: Pantoprazole Low dose<br>Cisplatin with standard hydration with pantoprazole 0.6 mg/kg | Drug: Pantoprazole low dose<br>* Pantoprazole 0.6 mg/kg<br>* Other names: zurcal;Other: Standard hydration<br>* Standard hydration alone<br>* Other names: Hydration;Drug: Cisplatin<br>* Cisplatin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with no renal toxicity | The number of patients with no renal toxicity | 6 months |
Post-Treatment Effects of Naltrexone

Study Overview
=================
Brief Summary
-----------------
The aims of this protocol are to compare 3 and 6 months of naltrexone treatment coupled with two psychotherapies that differ in scope and intensity. The effect of these treatments will be assessed with patients who differ in their psychosocial need and resources at their disposal, and in their level of cravings for alcohol.

Official Title
-----------------
Post-Treatment Effects of Naltrexone

Conditions
-----------------
Alcoholism

Intervention / Treatment
-----------------
* Drug: naltrexone (Revia)
* Behavioral: broad spectrum treatment
* Behavioral: motivational enhancement therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meets current diagnosis of alcohol dependence and have been abstinent for a minimum of 3 and maximum of 21 days prior to treatment Must be able to participate in an 18-month outpatient study, and live within a one hour or less commute to treatment facility. Must be fluent in English. Women of childbearing potential must have a negative pregnancy test. Exclusion Criteria: Severe hepatic disease or a liver function test greater than 4 times normal. Opiate use in the last 14 days or a history of opioid dependence in the past year. Pregnant or lactating females who are not using a reliable method of birth control. Inability to follow medication instructions and safety precautions. Comorbid substance dependence diagnosis in the past 6-months, excluding nicotine or marijuana dependence. Use of medications intended to decrease drinking. Meets criteria for bipolar disorder, schizophrenia, bulimia/anorexia, dementia, major depression.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: naltrexone (Revia)|nan|
|Behavioral: broad spectrum treatment|nan|
|Behavioral: motivational enhancement therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Preoperative Psychological Intervention on the Degree of Cooperation During Tracheal Catheter Extubation in Patients

Study Overview
=================
Brief Summary
-----------------
The patients in the experimental group received the relevant knowledge education in the recovery period 30 minutes before anesthesia. The operation time, anesthesia time, cooperation degree score, total cooperation rate and patient satisfaction were observed and recorded. Results: there was no significant difference in operation time and anesthesia time between the experimental group and the control group (P < 0.05). The percentage of patients in the experimental group was 20.12% and 70.89% respectively, while that in the control group was 40.32% and 20.73% respectively (P < 0.05). The total cooperation rate was 95.00% in the experimental group and 77.00% in the control group. There was significant difference between the two groups (P < 0.05). The satisfaction of patients in the experimental group was 95%. 65% of the patients in the control group were satisfied (P < 0.05). Conclusion: preoperative psychological intervention for patients with general anesthesia and endotracheal intubation can significantly reduce the restlessness and uncooperative phenomenon during extubation, and improve the cooperation rate and satisfaction of patients.

Official Title
-----------------
Effect of Preoperative Psychological Intervention on the Degree of Cooperation During Tracheal Catheter Extubation in Patients Under General Anesthesia During Awakening Period

Conditions
-----------------
Nurse's Role

Intervention / Treatment
-----------------
* Other: preoperative psychological intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the patients who will undergo cholecystectomy surgery Exclusion Criteria: the patients who can not well communicate

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: the experimental group received psychological intervention<br> | Other: preoperative psychological intervention<br>* including closing the relationship between nurse and patient , knowledge education,<br>|
| No Intervention: the control group receive normal process before surgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The total cooperation rate | The total cooperation rate was 95.00% in the experimental group and 77.00% in the control group. | through study completion, an average of half a year |
Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate

Study Overview
=================
Brief Summary
-----------------
In Japan, as well as in other countries, the dose of adalimumab (ADA) is limited to 40 mg every other week when used in combination with methotrexate (MTX) for patients with rheumatoid arthritis (RA). However, ADA 80 mg with MTX may be required for some RA patients, especially for those with high disease activity. Therefore, we tried to increase the ADA dose to 80 mg every other week with concomitant MTX, only if the disease activity did not decrease below moderate activity defined by DAS28 < 3.2. The primary endpoint was the rate of patients who achieved disease remission (DAS28 < 2.6) at 30 weeks with this predifined treatment strategy.

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: Adalimumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with rheumatoid arthritis receiving MTX ≧ 6 mg/week for at least 3 months disease activity : DAS28 > 5.1 Exclusion Criteria: allergy to ADA present active infection including TB history of demyelinating disease, HBV infection and malignancy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ADA 80 mg eow + MTX<br> | Drug: Adalimumab<br>* To increase the ADA dose from 40 mg eow to 80 mg eow<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of achieving remission at week 30 |  | 30 weeks |
Hypotension Prediction Effect on AKI

Study Overview
=================
Brief Summary
-----------------
It is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (HPI) on the prevention of acute kidney injury (AKI) after radical cystectomy. The primary hypothesis is that HPI software guidance prevents postoperative AKI by reducing the duration and severity of intraoperative hypotension (IOH).

Official Title
-----------------
Effect of Use of Hypotension Prediction System in Prevention of Postoperative Acute Kidney Injury in Radical Cystectomy

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Device: BP management with HPI guidance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≧ 19 Patients undergoing radical cystectomy with neobladder reconstruction Patients undergoing radical cystectomy with ileal conduit urinary diversion Exclusion Criteria: Unable to voluntarily give consent Unable to use both radial arteries due to such reasons: prior surgery on the radial artery, breast cancer history with axillary LN dissection, AV fistula for renal replacement therapy, or abnormal Allen's test.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HPI group<br>Managing intraoperative hemodynamic condition under the HPI guidance | Device: BP management with HPI guidance<br>* The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.<br>|
| No Intervention: Standard care group<br>Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute kidney injury | Occurrence of acute kidney injury after radical cystectomy | Seven day after the operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depth and duration of hypotension | Depth and duration of hypotension will be assessed by calculating time weighted average (TWA) of hypotension under mean arterial pressure under 65 mmHg during the operation | From applying HPI (hypotension prediction index) monitor to the arterial line to the end of the anesthesia | 
| Hypotension prediction index | Time weighted average of hypotension prediction index during the operation | From applying HPI (hypotension prediction index) monitor to the arterial line to the end of the anesthesia |
EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA

Study Overview
=================
Brief Summary
-----------------
First-line treatment with afatinib prolongs overall survival in patients with metastatic non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations. Conversely, somatic KRAS mutations are negative predictors for benefit from EGFR-targeting agents. In this study we want to compare a new highly sensitive method for the detection of EGFRdelEx19 and KRAS Exon 2 with targeted-resequencing multiplex-PCR (NGS).

Detailed Description
-----------------
First-line treatment with afatinib prolongs overall survival in patients with metastatic non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations. Conversely, somatic KRAS mutations are negative predictors for benefit from EGFR-targeting agents. Rapid availability of these biomarker results is mandatory to prevent delayed or inferior treatments. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is well-established for lung cancer diagnosis and staging. Next generation sequencing (NGS) via targeted resequencing allows simultaneous interrogation for multiple mutations, but has its limitations based on the amount of tumor tissue required and assay times. RT-PCR using Light-Cycler technology (LC-RTPCR) is a rapid and sensitive assay to detect somatic mutations in various tissues from NSCLC patients. The study's aim was to analyze if LC-RTPCR is feasible for rapid EGFRdelEx19 and KRAS Exon 2 mutation detection in EBUS-TBNA samples and to compare results with results obtained via standard NGS mutation analyses.

Official Title
-----------------
Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lymph Node Metastases From Patients With Lung Adenocarcinoma

Conditions
-----------------
Lung Adenocarcinoma Metastatic

Intervention / Treatment
-----------------
* Genetic: LC-RT-PCR and NGS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lung adenocarcinoma positive EBUS-TBNA specimen Exclusion Criteria: other diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detection of mutations |  | 1 year |
Prediction of Future Weight Change With Dopamine Transporter

Study Overview
=================
Brief Summary
-----------------
This is the re-analyzing study of observational study by Parkinson's Progression Markers Initiative

Official Title
-----------------
Prediction of Future Weight Change With Dopamine Transporter

Conditions
-----------------
Weight Change, Body

Intervention / Treatment
-----------------
* Diagnostic Test: I-123 FP-CIT Single photon emission tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males or females with their age of 30 years or older at screening Exclusion Criteria: subjects with a neurological disorder, a first degree relative with idiopathic PD, Montreal Cognitive Assessment score of 26 or less, medications that might interfere with DAT SPECT scans, anticoagulants that might preclude safe completion of the lumbar puncture, or investigational drugs, and a condition that precludes the safe performance of routine lumbar puncture

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight change | weight change per year until 5 years after SPECT | 1, 2, 3, 4, 5 year after SPECT |
Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head

Study Overview
=================
Brief Summary
-----------------
We are expecting that there are remarkable differences location at BaiHui(GV20) or Houding(GV19)showing from same person in our study.

Official Title
-----------------
Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head

Conditions
-----------------
to Research the Feasibility of the Proportional Bone(Skeletal) Measurement Method on the Head Region.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers Exclusion Criteria: craniectomy Psychotic symptoms

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| adult<br>100 volunteers age ranged 18-80 years old | |
| children<br>60 children under 10 years old. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acupuncture
pedCAPNETZ - Community Acquired Pneumonia (CAP) in Childhood and Adolescence

Study Overview
=================
Brief Summary
-----------------
Establishment of a study network and patient cohort for pediatric CAP

Detailed Description
-----------------
The aim of the project is the development of a large pediatric CAP patient cohort based on the established pedCAPNETZ pilot cohort. The main objective is to improve knowledge on etiology, epidemiology, diagnosis and management of pediatric CAP in a developed country. pedCAPNETZ will enable the systematic and detailed characterization of pediatric CAP cases on an epidemiological, clinical and biological level.

Official Title
-----------------
pedCAPNETZ - Development and Detailed Characterization of a Cohort for Community Acquired Pneumonia (CAP) in Childhood and Adolescence

Conditions
-----------------
Community-acquired Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age < 18 symptoms of an acute lower respiratory tract infection with radiological confirmed pneumonia via ultrasound or chest x-ray Exclusion Criteria: hospitalization for any reason within the last 28 days congenital or acquired immunodeficiency concomitant respiratory disease with impaired mucociliary clearance such as cystic fibrosis, primary ciliary dyskinesia, tracheostomy or other severe lung disease including pulmonary tuberculosis, malignancy, and cytostatic therapy during past 28 days or neutropenia (< 1000/µl) or relevant immunosuppressive treatment

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with pediatric community acquired pneumonia (pedCAP) across all different levels of health care | To establish a multicenter national, prospective, observational and longitudinal pedCAP database and collaborative research network | 5 years | 
| Prevalence of pedCAP and etiologies (composite outcome measures) across all different levels of health care | Etiology of pedCAP in Germany Clinical presentation of pedCAP Predictors of severe clinical course of pedCAP Diagnostics employed in management of pedCAP Microbiology and virology of pedCAP Radiology of pedCAP Comorbidity in patients with pedCAP Treatment patterns of pedCAP | 5 years |